WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$5.86 USD
-0.04 (-0.68%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $5.87 +0.01 (0.17%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
WAVE Life Sciences Ltd. [WVE]
Reports for Purchase
Showing records 21 - 40 ( 61 total )
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
WVE-004 Demonstrates Target Engagement in Phase 1 ALS/FTD Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Multiple Shots on Goal Across Diverse CNS Pipeline Define 2022; Reiterate Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
With Steady Progress Across Pipeline, We Choose to Focus on WVE-N531; Reit Buy and $10PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Preclinical Data Highlights Frame Clinical Expectations for 2022; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Under the Radar - Wave''s "ADAR" Program Gives PRISM Additional Depth
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
PRISM Platform Charts Course for ALS and FTD, While Revisiting HD and DMD; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
PRECISION-HD Trials Fail to Deliver in HD, While WVE-003 Aims for a Win; Reit Buy and Lowering Our PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
PRECISION HD-1 and HD-2 Data Imminent; Multiple PN-Chemistry Assets Set to Enter the Clinic in 2021;Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Assuming Coverage With Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
In the Meantime, a Look Down the Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
2Q20 Update; HD-1 and 2 Readouts Now Anticipated During 1Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
On Track to Unveil PRECISION HD-1 and HD-2 During 2H20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Bringing a Wallet to a Hammer and Sickle Fight, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: WAVE Life Sciences Ltd.
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D